CEL SCI CORP (NASDAQ:CVM) has seen notable insider transactions involving its leadership, alongside several major corporate announcements that signal strategic expansion efforts. On May 14, 2026, the de Clara Trust, which is managed by Chief Executive Officer Geert R. Kersten, acquired a block of common stock shares. This transaction was reported via a recent SEC filing.
Specifically, the trust purchased 300,000 shares of CEL SCI's common stock at $1.20 per share. The total value generated by this acquisition amounted to $360,000. These shares were restricted stock purchased directly from the company using the closing price available on May 13, 2026.
The current trading valuation of CEL SCI's common stock is reported at $1.43. This represents an increase compared to its 52-week low of $0.89, though it remains substantially lower than the 52-week high recorded at $13.48.
Impact on Executive Holdings
Following this reported purchase by the de Clara Trust, Mr. Kersten's indirect holdings through the trust increased to 311,547 shares of CEL SCI common stock. Furthermore, he maintains a direct holding of 210,950 shares of the company’s common stock.
This insider buying activity is noted as the company navigates challenging operational periods. One financial assessment points out that the corporation is rapidly consuming cash reserves and has experienced a decline in its stock price of 78.6% over the preceding six months.
Strategic Capital Raises and Partnerships
Beyond the insider transactions, CEL SCI Corporation recently executed significant corporate milestones. The company completed a public offering involving 6 million shares of common stock. This sale occurred at a price point of $1.20 per share, generating approximate gross proceeds totaling $7.2 million.
ThinkEquity served as the sole placement agent for this capital raise, which was contingent upon customary closing conditions being met. In conjunction with the public offering, CEL SCI also announced a strategic partnership and distribution agreement with Amarox. This collaboration focuses on managing the regulatory affairs and potential commercialization of CEL-SCI's product, Multikine, specifically within Saudi Arabia.
The terms of this agreement are detailed: it includes an optional extension to other Gulf Cooperation Council countries. Crucially, the agreement establishes a 50-50 net revenue sharing arrangement derived from Multikine sales in Saudi Arabia. This revenue sharing is conditional upon the successful receipt of Breakthrough Medicine Designation from the Saudi Food and Drug Authority (SFDA). Amarox's role extends beyond distribution; they will function as the local regulatory representative, leading communications with the SFDA.
These reported developments represent significant strategic steps for CEL-SCI in efforts to expand its market presence globally. The combination of capital infusion and focused international agreements suggests a concerted effort toward growth and operational stability.